Shandong Jincheng Pharmaceutical Group Co., Ltd Share Price

Equities

300233

CNE100001500

Pharmaceuticals

End-of-day quote Shenzhen S.E. 23:00:00 25/04/2024 BST 5-day change 1st Jan Change
16.51 CNY +1.85% Intraday chart for Shandong Jincheng Pharmaceutical Group Co., Ltd +8.62% -0.90%

Financials

Sales 2022 3.51B 484M 38.75B Sales 2023 3.54B 488M 39.11B Capitalization 6.34B 874M 70.04B
Net income 2022 273M 37.68M 3.02B Net income 2023 175M 24.15M 1.93B EV / Sales 2022 2.43 x
Net cash position 2022 208M 28.74M 2.3B Net cash position 2023 471M 64.94M 5.2B EV / Sales 2023 1.66 x
P/E ratio 2022
32.1 x
P/E ratio 2023
37 x
Employees 3,806
Yield 2022
0.66%
Yield 2023
1.2%
Free-Float 29.66%
More Fundamentals * Assessed data
Dynamic Chart
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2023, Payable on May 8, 2024 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Shandong Jincheng Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on February 2, 2024. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd's Equity Buyback announced on February 2, 2024, has closed with 4,543,000 shares, representing 1.18% for CNY 55 million. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd announces an Equity Buyback for CNY 70 million worth of its shares. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd authorizes a Buyback Plan. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jincheng Pharmaceutical Gets License to Produce E-Cigarette Nicotine MT
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Approves Directorate Appointments CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Approves Cash Dividend for the Year 2022 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for 2022 CI
Three Jincheng Pharmaceutical Medicines Shortlisted For China’s Drug Procurement Program MT
More news
1 day+1.85%
1 week+8.62%
Current month+7.28%
1 month+6.11%
3 months+15.21%
6 months-6.46%
Current year-0.90%
More quotes
1 week
14.96
Extreme 14.96
16.54
1 month
14.81
Extreme 14.81
17.00
Current year
10.83
Extreme 10.83
17.05
1 year
10.83
Extreme 10.83
22.09
3 years
10.83
Extreme 10.83
44.98
5 years
10.83
Extreme 10.83
44.98
10 years
9.94
Extreme 9.935
59.83
More quotes
Managers TitleAgeSince
President 52 31/01/08
Director of Finance/CFO 48 -
Chief Tech/Sci/R&D Officer 60 31/12/03
Members of the board TitleAgeSince
Chairman 47 30/06/04
President 52 31/01/08
Chief Tech/Sci/R&D Officer 60 31/12/03
More insiders
Date Price Change Volume
26/04/24 16.51 +1.85% 5,568,190
25/04/24 16.21 +3.78% 6,766,101
24/04/24 15.62 +1.03% 3,144,800
23/04/24 15.46 +1.18% 3,776,105
22/04/24 15.28 +0.53% 3,515,601

End-of-day quote Shenzhen S.E., April 25, 2024

More quotes
Shandong Jincheng Pharmaceutical Group Co., Ltd., formerly Shandong Jincheng Pharmaceutical Co., Ltd., is a China-based company principally engaged in the research, development, production and sale of cephems medicine intermediates. The Company mainly provides active ester side chain of cephalosporin products, other pharmaceutical chemical products, as well as bio-pharmaceuticals and specialty active pharmaceutical ingredient (API). The Company distributes its products within domestic market and to overseas markets.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300233 Stock